Exalenz Bioscience Ltd. (TASE:EXEN) reports that its BreathID diagnostic kit successfully monitored a treatment for gastroesophageal reflux (GER) - dyspepsia - in a trial by Pfizer Inc. (NYSE: PFE; LSE: PFZ). GER is currently monitored with MRIs and antiacids.
The success will have no direct effect on the registration of BreathID for marketing as a diagnostic tool for GER in clinical conditions, but it is significant for the product's reputation and it strengthens' Exalenz's relations with Pfizer. Last week, Exalenz reported that Pfizer was suspending its clinical trial for non alcoholic steatohepatitis (NASH) fatty liver, which used the BreathID.
In addition, the information accumulated in the present trial may be usable as support data if and when Exalenz decides to register BreathID as a standalone product. Exalenz CEO Dr. Uri Geiger said, "The product is ready for clinical trials in this indication too, but we have no resources to begin multiple simultaneous trials."
Exalenz already has US Food and Drug Administration (FDA) and EU CE Mark certification to market BreathID.
Published by Globes [online], Israel business news - www.globes-online.com - on September 18, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008